Many tools and strategies can help dermatologists overcome their discomfort in addressing psoriatic arthritis (PsA) in patients with psoriasis, physicians report.
Newer biologics that target interleukin (IL)-17 and IL-23 are changing the paradigm for psoriasis treatment, report physicians.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%